Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Culmerciclib - Chia Tai Tianqing Pharmaceutical Group

Next Previous
Drug Profile

Culmerciclib - Chia Tai Tianqing Pharmaceutical Group

Alternative Names: TQB-3616

Latest Information Update: 16 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class 2 ring heterocyclic compounds; Alkanes; Amines; Antineoplastics; Benzene derivatives; Fluorinated hydrocarbons; Indazoles; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered HER2 negative breast cancer
  • Phase II Liposarcoma; Lung cancer

Most Recent Events

  • 16 Dec 2025 Chemical structure information added.
  • 12 Dec 2025 Chia Tai Tianqing Pharmaceutical Group completes the enrolment of its Phase-III clinical trials in HER2-negative-breast-cancer (Adjuvant therapy, Combination therapy) in China (PO)
  • 09 Dec 2025 Registered for HER2-negative-breast-cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (PO) - First global approval

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top